{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:15:57Z","timestamp":1790712957625,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","award":["322176"],"award-info":[{"award-number":["322176"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ero.2025.11.023","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T22:26:54Z","timestamp":1767220014000},"page":"79-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antirheumatic medication use among pregnant women with rheumatoid arthritis: a Norwegian nationwide drug utilisation study"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4208-791X","authenticated-orcid":false,"given":"Eun-Young","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4853-4434","authenticated-orcid":false,"given":"Marleen M H J","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1704-6067","authenticated-orcid":false,"given":"Benjamin P","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9878-4779","authenticated-orcid":false,"given":"In-Sun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6361-2918","authenticated-orcid":false,"given":"Hedvig M E","family":"Nordeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ero.2025.11.023_bib0001","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/ar2825","article-title":"Why are women predisposed to autoimmune rheumatic diseases?","volume":"11","author":"Oliver","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.ero.2025.11.023_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000878","article-title":"Impact of autoimmune rheumatic diseases on birth outcomes: a population-based study","volume":"5","author":"Strouse","year":"2019","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.ero.2025.11.023_bib0003","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41584-019-0240-8","article-title":"Stratifying management of rheumatic disease for pregnancy and breastfeeding","volume":"15","author":"Giles","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.11.023_bib0004","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/ar2591","article-title":"Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study","volume":"11","author":"Sokka","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.ero.2025.11.023_bib0005","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/rheumatology\/key053","article-title":"Risk for adverse pregnancy outcome in axial spondyloarthritis and rheumatoid arthritis: disease activity matters","volume":"57","author":"Zbinden","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.ero.2025.11.023_bib0006","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/art.24003","article-title":"Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study","volume":"59","author":"de Man","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ero.2025.11.023_bib0007","first-page":"9","article-title":"High rate of preterm birth in pregnancies complicated by rheumatoid arthritis","volume":"31","author":"Langen","year":"2014","journal-title":"Am J Perinatol"},{"issue":"5","key":"10.1016\/j.ero.2025.11.023_bib0008","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.autrev.2014.12.011","article-title":"State of the art: reproduction and pregnancy in rheumatic diseases","volume":"14","author":"\u00d8stensen","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.ero.2025.11.023_bib0009","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/art.21663","article-title":"Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis","volume":"54","author":"Chakravarty","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ero.2025.11.023_bib0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/03009742.1998.11720781","article-title":"Obstetrical and neonatal outcome in pregnant patients with rheumatic disease","volume":"107","author":"Skomsvoll","year":"1998","journal-title":"Scand J Rheumatol Suppl"},{"issue":"4","key":"10.1016\/j.ero.2025.11.023_bib0011","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/ard.2008.105262","article-title":"Increased risk of adverse pregnancy outcomes in women with rheumatoid arthritis: a nationwide population-based study","volume":"69","author":"Lin","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"7411","key":"10.1016\/j.ero.2025.11.023_bib0012","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/bmj.327.7411.368","article-title":"Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study","volume":"327","author":"Li","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ero.2025.11.023_bib0013","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.reprotox.2003.10.007","article-title":"Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study","volume":"18","author":"Gur","year":"2004","journal-title":"Reprod Toxicol"},{"issue":"6","key":"10.1016\/j.ero.2025.11.023_bib0014","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/kez405","article-title":"Oral corticosteroid use during pregnancy and risk of preterm birth","volume":"59","author":"Palmsten","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.ero.2025.11.023_bib0015","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/ard-2022-222679","article-title":"Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients' offspring","volume":"81","author":"Smeele","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ero.2025.11.023_bib0016","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ard.2025.02.023","article-title":"EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update","volume":"84","author":"R\u00fcegg","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ero.2025.11.023_bib0017","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jaci.2021.07.005","article-title":"Safety of anti-TNF agents in pregnancy","volume":"148","author":"De Felice","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.ero.2025.11.023_bib0018","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/pds.1775","article-title":"Use of antirheumatic drugs in mothers and fathers before and during pregnancy-a population-based cohort study","volume":"18","author":"Viktil","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.ero.2025.11.023_bib0019","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03009742.2011.626442","article-title":"Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers","volume":"41","author":"Viktil","year":"2012","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"10.1016\/j.ero.2025.11.023_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004091","article-title":"Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study","volume":"10","author":"Andreoli","year":"2024","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.ero.2025.11.023_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-065189","article-title":"Comanagement with rheumatology and prescription biologics filled during pregnancy in women with rheumatic diseases: a retrospective analysis of US administrative claims data","volume":"12","author":"Shridharmurthy","year":"2022","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.ero.2025.11.023_bib0022","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1093\/rheumatology\/keab894","article-title":"Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis: a matched cohort study from Sweden and Denmark","volume":"61","author":"Hellgren","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ero.2025.11.023_bib0023","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/RHU.0000000000002090","article-title":"Perinatal use and discontinuation of disease-modifying antirheumatic drugs: outcomes of patients seen at a pregnancy and rheumatic diseases clinic","volume":"30","author":"Rebi\u0107","year":"2024","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.ero.2025.11.023_bib0024","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1034\/j.1600-0412.2000.079006435.x","article-title":"The medical birth registry of norway. Epidemiological research and surveillance throughout 30 years","volume":"79","author":"Irgens","year":"2000","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"Suppl 2","key":"10.1016\/j.ero.2025.11.023_bib0025","first-page":"S48","article-title":"The Norwegian Prescription Database (NorPD): new register for pharmacoepidemiological research covering a whole nation","volume":"14","author":"Furu","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ero.2025.11.023_bib0026","unstructured":"Helsedirektoratet. Norsk kontroll og utbetaling av helserefusjoner databasen\u2014Norwegian Control and Payment of Health Reimbursements Database. Accessed April 15, 2025. Available from: https:\/\/helsedata.no\/no\/forvaltere\/helsedirektoratet\/kontroll-og-utbetaling-av-helserefusjoner-kuhr\/"},{"issue":"4","key":"10.1016\/j.ero.2025.11.023_bib0027","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","article-title":"British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"Russell","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ero.2025.11.023_bib0028","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/AOG.0b013e3182a603bb","article-title":"Development of a comorbidity index for use in obstetric patients","volume":"122","author":"Bateman","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.ero.2025.11.023_bib0029","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1177\/0962280216673085","article-title":"Group-based multi-trajectory modeling","volume":"27","author":"Nagin","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.ero.2025.11.023_bib0030","series-title":"Group-Based Modeling of Development","author":"Nagin","year":"2005"},{"key":"10.1016\/j.ero.2025.11.023_bib0031","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","article-title":"Group-based trajectory modeling in clinical research","volume":"6","author":"Nagin","year":"2010","journal-title":"Annu Rev Clin Psychol"},{"issue":"1","key":"10.1016\/j.ero.2025.11.023_bib0032","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev-clinpsy-081122-012416","article-title":"Recent advances in group-based trajectory modeling for clinical research","volume":"20","author":"Nagin","year":"2024","journal-title":"Annu Rev Clin Psychol"},{"key":"10.1016\/j.ero.2025.11.023_bib0033","unstructured":"U.S. Food and Drug Administration. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid 2020 [updated 2020 Oct 15]. Accessed April 15, 2025. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic"},{"key":"10.1016\/j.ero.2025.11.023_bib0034","unstructured":"European Medicines Agency. Arava (leflunomide) EPAR \u2013 product information. Available from: Arava | European Medicines Agency (EMA). Accessed April 15, 2025."},{"issue":"3","key":"10.1016\/j.ero.2025.11.023_bib0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/ar1957","article-title":"Anti-inflammatory and immunosuppressive drugs and reproduction","volume":"8","author":"\u00d8stensen","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.ero.2025.11.023_bib0036","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/rheumatology\/ker302","article-title":"Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use","volume":"50","author":"Hazes","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ero.2025.11.023_bib0037","unstructured":"Mayo Clinic Staff. Rheumatoid arthritis: does pregnancy affect symptoms? Accessed April 15, 2025. Available from: https:\/\/www.mayoclinic.org\/diseases-conditions\/rheumatoid-arthritis\/in-depth\/rheumatoid-arthritis-pregnancy\/art-20094103"},{"issue":"5","key":"10.1016\/j.ero.2025.11.023_bib0038","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/ALN.0000000000000172","article-title":"Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States","volume":"120","author":"Bateman","year":"2014","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.ero.2025.11.023_bib0039","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1186\/s12913-023-09975-7","article-title":"Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010\u20132019)","volume":"23","author":"Brkic","year":"2023","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"10.1016\/j.ero.2025.11.023_bib0040","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/acr.20422","article-title":"Patterns of medication use during pregnancy in rheumatoid arthritis","volume":"63","author":"Kuriya","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.ero.2025.11.023_bib0041","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40801-024-00416-3","article-title":"Disease-modifying medications in patients with rheumatoid arthritis in the USA: Trends from 2016 to 2021","volume":"11","author":"Peasah","year":"2024","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.ero.2025.11.023_bib0042","unstructured":"American College of Obstetricians and Gynecologists. Immune modulating therapies in pregnancy and lactation. Committee Opinion No. 776 (Reaffirmed 2021) 2019, Accessed April 15, 2025. Available from: https:\/\/www.acog.org\/clinical\/clinical-guidance\/committee-opinion\/articles\/2019\/04\/immune-modulating-therapies-in-pregnancy-and-lactation"},{"issue":"5","key":"10.1016\/j.ero.2025.11.023_bib0043","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"G\u00f6testam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ero.2025.11.023_bib0044","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ero.2025.11.023_bib0045","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/1947-2714.93377","article-title":"Pregnant women and non-steroidal anti-inflammatory drugs: knowledge, perception and drug consumption pattern during pregnancy in Ethiopia","volume":"4","author":"Kassaw","year":"2012","journal-title":"N Am J Med Sci"},{"issue":"8","key":"10.1016\/j.ero.2025.11.023_bib0046","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1111\/bcp.15732","article-title":"Paracetamol use prior to and in early pregnancy: prevalence and patterns among women with and without chronic medical diseases","volume":"89","author":"Taagaard","year":"2023","journal-title":"Br J Clin Pharmacol"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125001235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125001235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:52:36Z","timestamp":1787716356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708125001235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S3050708125001235"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.11.023","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antirheumatic medication use among pregnant women with rheumatoid arthritis: a Norwegian nationwide drug utilisation study","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}